Assessment of cognitive functions in animal models of schizophrenia

被引:0
|
作者
Agnieszka Nikiforuk
机构
[1] Institute of Pharmacology,Department of Behavioral Neuroscience and Drug Development
[2] Polish Academy of Sciences,undefined
来源
Pharmacological Reports | 2018年 / 70卷
关键词
Cognition; Schizophrenia; Translation; Neurocognitive tests; Rodent models;
D O I
暂无
中图分类号
学科分类号
摘要
Impaired cognitive functioning is recognized as an integral feature of schizophrenia. These deficits have emerged not only as an important predictor of clinical and social outcomes but also as a target for schizophrenia therapeutics. Several cognitive functions have been identified as being commonly deficient in schizophrenia patients, including attention, working memory, reasoning and problem solving, visual learning and memory or social cognition. The selected neuropsychological tests measuring these specific domains were included in the MATRICS Consensus Cognitive Battery (MCCB) and in the Cambridge Neuropsychological Test Automated Battery (CANTAB). While the MCCB and the CANTAB are used in clinical trials of cognition-enhancing drugs for schizophrenia, there is a growing need for a translational test battery that can be used in animal models. To reduce the translational gap between preclinical and clinical studies, the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CINTRICS) programme has recommended animal tasks with construct validity for the evaluation of cognitive domains that are affected in schizophrenia. This review will overview rodent tests that are widely used to identify schizophrenia-like cognitive impairments, including CINTRICS’s recommendations and novel touchscreen-based procedures.
引用
收藏
页码:639 / 649
页数:10
相关论文
共 50 条
  • [1] Assessment of cognitive functions in animal models of schizophrenia
    Nikiforuk, Agnieszka
    PHARMACOLOGICAL REPORTS, 2018, 70 (04) : 639 - 649
  • [2] Animal models for the assessment of cognitive dysfunctions in schizophrenia:: focus on the nitric oxide pathway
    Klamer, D. S.
    Palsson, E. N.
    Wass, C. E.
    Fejgin, K. W.
    Finnerty, N. J.
    Lowry, J. P.
    Engel, J. A.
    Svensson, L. I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S188 - S189
  • [3] Assessment of cognitive function in animal models
    Kotani, Sadaharu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S83 - S83
  • [4] Innovation of animal models for cognitive impairment in schizophrenia (CIS)
    Ikeda, Kazuhito
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2012, 118 : 22P - 22P
  • [5] Paliperidone improves cognitive but not social defects in animal models of schizophrenia
    Koenig, J. I.
    Shelton, S.
    Taylor, A.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 474 - 474
  • [6] Animal models of schizophrenia: The interface between neuropharmacology and cognitive deficit
    Joseph, MH
    Young, AMJ
    Moran, P
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 412 - 412
  • [7] Effects of Immunomodulatory Peptide Y On Cognitive Functions in Animal Models
    Lemieszewska, M.
    Stanczykiewicz, B.
    Jakubik-Witkowska, M.
    Zambrowicz, A.
    Polanowski, A.
    Rymaszewska, J.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [8] Animal models of schizophrenia
    Jones, C. A.
    Watson, D. J. G.
    Fone, K. C. F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (04) : 1162 - 1194
  • [9] Animal models of schizophrenia
    De Hert, M
    Ellenbroek, B
    NEUROSCIENCE RESEARCH COMMUNICATIONS, 2000, 26 (03) : 279 - 288
  • [10] Animal models for schizophrenia
    Wolterink, G
    Daenen, EWPM
    Van Ree, JM
    NEUROSCIENCE RESEARCH COMMUNICATIONS, 2000, 27 (03) : 143 - 154